Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Obstetrics/Gynecology (Women’s Health) | Endocrinology | Family Medicine
Disease Category: Ovarian Cancer
Location: United States, ND

Clinical Trial Details

Overview

Research Study Summary

Advanced Ovarian Cancer

Purpose

To investigate the efficacy and safety of BIBF 1120 plus chemotherapy as compared to placebo plus chemotherapy in patients with advanced ovarian cancer

Patient Inclusion Criteria:

  • Patients with histologically proven epithelial ovarian cancer, fallopian tube or primary peritoneal cancer of advanced stage, 18 + years of age, life expectancy of at least 6 months

Patient Exclusion Criteria:

  • histologic diagnosis of a benign or borderline tumour or of a malignant tumour of non-epithelial origin of the ovary, the fallopian tube or the peritoneum, clinically relevant non-healing would, ulcer or bone fracture, clinical symptoms of brain metastases

To Learn more
Phase

3

Gender

Female

Age

18 and up

Overall Status

Recruiting

Facility Type

N/A

Contact

Dr. Tom Davis, Director of Business Development
Legacy Pharma Research
601 N. 5th St.
Bismarck, ND 58501
Phone: 701-751-1128
Fax: 701-751-1131

View Map

If you would like to learn more about participating in this research study, please email the trial contact using the form below.

Name:
Address:
City:
State:
Zip/Postal Code:
Country:
Phone:
Email:  
Message:
 
Please leave this field empty.

CW ID: 163103

Date Last Changed: July 24, 2013


DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.